Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | HTR2C | P28335 | 4/20 | 0.34 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.34 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27166122 | 0.90 | HSP90AA1 (0.41) | HSP90AA1PRMT5WDR77AKR1C3GRM1 | |
| SCHEMBL29205181 | 0.89 | PROKR1 (0.42) | HSP90AA1PRMT5WDR77RAB9AAKR1C3 | |
| SCHEMBL29205149 | 0.89 | HSP90AA1 (0.39) | HSP90AA1PRMT5WDR77AKR1C3MEN1 | |
| SCHEMBL30055616 | 0.89 | HSP90AA1 (0.39) | HSP90AA1PRMT5WDR77AKR1C3MEN1 | |
| SCHEMBL29205179 | 0.86 | HSP90AA1 (0.37) | HSP90AA1PRMT5WDR77AKR1C3PROKR1 | |
| SCHEMBL27166096 | 0.86 | PROKR1 (0.47) | HSP90AA1PRMT5WDR77RAB9ANPC1 | |
| SCHEMBL27166144 | 0.85 | HSP90AA1 (0.41) | HSP90AA1PRMT5WDR77RAB9APROKR1 | |
| SCHEMBL29205121 | 0.83 | NPC1 (0.46) | RAB9AAKR1C3ALDH1A1NPC1MEN1 | |
| SCHEMBL30828288 | 0.83 | NPC1 (0.46) | RAB9AAKR1C3ALDH1A1NPC1MEN1 | |
| SCHEMBL29205127 | 0.81 | ALOX5 (0.42) | RAB9AAKR1C3ALDH1A1NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637471-B2 | Heterocyclic compounds, compositions, methods of preparation and uses thereof | ORGANON R&D FINLAND LTD. (FI) | 2026-05-26 | — | — | US | disclosed |
| EP-4334289-B1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | Organon R&D Finland Oy (FI) | 2025-06-25 | — | — | EP | disclosed |
| US-20240254131-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | ORGANON R&D FINLAND LTD. (FI) | 2024-08-01 | — | — | US | disclosed |
| CN-117794899-A | Novel heterocyclic compounds, compositions, methods of preparation and uses thereof | 欧加农研发芬兰有限公司 | 2024-03-29 | — | — | CN | disclosed |
| EP-4334289-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | Organon R&D Finland Ltd (FI) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022234193-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | FORENDO PHARMA LTD (FI) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254131-A1 | NOVEL HETEROCYCLIC COMPOUNDS, COMPOSITIONS, METHODS OF PREPARATION AND USES THEREOF | AKR1C3, AKR1C4, AKR1C1 | HSP90AA1 2620/4885PRMT5 2943/4885WDR77 4100/4885 |
| US-12637471-B2 | Heterocyclic compounds, compositions, methods of preparation and uses thereof | AKR1C3, AKR1C4, AKR1C2 | HSP90AA1 1543/4885PRMT5 2872/4885WDR77 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.